Lacosamide Glenmark (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and limits repetitive firing. Additionally, it modulates the CRMP2 protein, further reducing neuronal excitability and helping to prevent the spread of epileptic activity.

The specific dose of Lacosamide Glenmark is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of Lacosamide during pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Lacosamide Glenmark, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide is distinct for its selective enhancement of slow sodium‑channel inactivation, which may offer better tolerability compared with traditional sodium‑channel blockers that affect fast inactivation. It is often chosen as an add‑on therapy when patients need additional seizure control without significant drug‑drug interactions.

Lacosamide Glenmark tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Lacosamide Glenmark is administered orally as a tablet. Patients should swallow the tablet whole with water, typically once or twice daily as directed by their prescriber. The exact schedule depends on the individual treatment plan and should be followed precisely.

Serious risks include the potential for suicidal thoughts or behavior, severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities like PR‑interval prolongation, and rare cases of liver injury. Patients should be monitored closely for any of these signs and report them immediately to a healthcare provider.

Lacosamide Glenmark should be avoided in patients with known hypersensitivity to lacosamide or any of its excipients, and in individuals with significant cardiac conduction disorders (e.g., advanced AV block) unless a pacemaker is present. It is also contraindicated in patients taking medications that cause severe, uncontrolled interactions.